Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q53577002

about

Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan Adrenal insufficiency: etiology, diagnosis and treatment.Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.Sunitinib Induced Immune Thrombocytopenia.Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.Endocrine side effects of broad-acting kinase inhibitors.IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction.VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro.FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors.Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors Vascular development in mouse lung metastases.Molecular profiling of childhood cancer: Biomarkers and novel therapies Enhanced Functional Genomic Screening Identifies Novel Mediators of Dual Leucine Zipper Kinase-Dependent Injury Signaling in Neurons.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.Angiogenesis and its therapeutic opportunities Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma.Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.

P2860

Q22305863-4A2AA7D3-542D-4842-885A-76D20F7E6527 Q24297412-7AC44F61-C7AC-4BC4-B3B4-F84D46D67178 Q24647897-4288C496-91E4-43CC-89AC-4C75C4BE1C79 Q27027632-B8146441-2397-4201-9972-3058B36B012D Q27693268-B584BE40-B7EA-4C33-80E3-2C662C6AD615 Q29012696-DBBDF6FF-3F32-4BFE-866A-BD1CC98270BF Q30455612-D4A43FA6-1325-4741-B27E-4F9E9924EA3E Q30474759-49052BF4-DE64-4CAA-ADE6-3164DA0E1F78 Q33385649-B24CB406-F09E-4492-A3FB-A62244C27E6E Q33428370-F37E51A1-72CD-486D-A3FE-29E20A422755 Q33467424-AC7EEA55-213F-4BC8-B84E-A6D8F0F8E8CA Q33665043-D52FD2C7-439F-40DF-A9B9-859D6BA9478F Q34202396-D9FBEFBD-7AB5-4075-B504-F7FA37BCC55E Q34226634-83BC4A51-9768-43B9-9512-C741E8D43CFD Q34567910-F47A246B-5F62-4FB1-8065-ED2272563297 Q34574985-C5AB03B0-89F2-45EA-950A-F81852A857F5 Q34647501-7417CE97-01FF-4F75-96FD-195C2B98B0CD Q34670026-3920E560-F399-4FF9-B421-78C0EB537AF4 Q34983846-68FDCC1E-D3C0-4B8F-9898-0AD371D472FE Q35039240-A13BB90F-0438-4A8B-9BC7-45DEC60B3D7E Q35083762-683C2F18-4547-46C5-9A79-9E310744091E Q35112894-AB73271D-B322-41ED-996C-3282A1B3A2E8 Q35563524-18D3D238-FCF4-4BFA-8FE9-C8A73B8934DC Q35572636-114E90E6-397B-4976-B678-680356CF1475 Q35584012-BB8A30DF-0363-4A32-9EAE-82725839AE9F Q35799223-610CF32E-D066-49B8-B437-1650C7B80B3A Q35886697-5934B00A-80FD-4F4D-8B0D-4296D6A9EEF5 Q36206495-65F6837B-B832-44BF-AD73-054FF6851FD2 Q36250783-37DB77A0-3AE7-47DD-9CBC-0860D27074AF Q36412675-107D2E6A-44F7-4D9B-9294-4A7C9FBEAAB8 Q36736494-46A09C02-929D-4DBD-8DFC-D136F1A1DA21 Q36858013-84F7CD82-07F5-489E-88EC-2F47CEB3369B Q36881812-9E7AEA8F-6166-4E53-B90C-59D152CB2940 Q37101283-6B323BEC-B256-4F15-863D-47811730C5D3 Q37153399-0022F27B-5C7D-4C54-9AEF-7F1A4F148E52 Q37188016-0572E276-1B36-4CE2-BE8D-109478762261 Q37366059-070F5634-1D28-476E-904E-7B1025FC09E9 Q37581359-14C9EBAF-D663-4F84-9DE8-617C5B0C6BE8 Q37594014-08741BB6-CE9E-4F17-B7B1-EB2973BE9A34 Q37629866-559B8FCD-71D9-4B33-AB10-0FEB871B2819

P2860

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q53577002

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Food and Drug Administration d ...... advanced renal cell carcinoma.

@en

Food and Drug Administration d ...... advanced renal cell carcinoma.

@nl

type

label

Food and Drug Administration d ...... advanced renal cell carcinoma.

@en

Food and Drug Administration d ...... advanced renal cell carcinoma.

@nl

prefLabel

Food and Drug Administration d ...... advanced renal cell carcinoma.

@en

Food and Drug Administration d ...... advanced renal cell carcinoma.

@nl

P1433

Q53577002-67E87D92-DC94-4AC1-8920-BD6BBC3E334F

P1476

Q53577002-EE2988B2-8A57-494C-863A-B281E808C62B

P2093

Q53577002-21CC03CC-86F9-40F0-AFDD-1DCE8051CF81

Q53577002-2218D366-458F-42C3-AD85-D03C5BA80518

Q53577002-5DD6CB84-EC6F-4DAB-BB8F-712E2B621516

Q53577002-7D814884-22F8-4595-B8FC-0193DDEC0A09

Q53577002-97331A44-090C-43CE-8C4E-7DA4B978BB01

Q53577002-A778BB7D-159A-4EF5-86E0-A679601987AD

Q53577002-B5AD9792-9B71-4C3E-BDB9-4582C86F2DE1

Q53577002-BE16D356-8A25-46F7-8B9D-64A298F7B283

Q53577002-F3215EB7-9F16-4F1D-8BB7-2AB0F38B0B3D

P304

Q53577002-5756844B-921E-44E5-8664-77DC27CA51A0

P31

Q53577002-2C5641F7-D355-4BAF-A50C-2E047407A7A9

P356

Q53577002-11B76CDD-0E72-449C-AFB3-191EC00C3652

P433

Q53577002-CBDB8B39-A673-45A4-B8B5-F43C5BA285F6

P478

Q53577002-B199AF1E-F5F0-48A9-8B60-5986DBBA57E2

P577

Q53577002-8B9A959B-E5A4-4C9D-93C2-96E415C1385F

P5875

Q53577002-D14BD73B-3D05-4BBE-9952-87BA4325B118

P698

Q53577002-A53F4D49-8D23-4A00-97B6-376547CC2553

P356

THEONCOLOGIST.12-1-107

P1433

P1476

Food and Drug Administration d ...... advanced renal cell carcinoma.

@en

P2093

David Morse

http://www.w3.org/2001/XMLSchema#string

Edwin P Rock

http://www.w3.org/2001/XMLSchema#string

Janet X Jiang

http://www.w3.org/2001/XMLSchema#string

Kooros Mahjoob

http://www.w3.org/2001/XMLSchema#string

Ramzi Dagher

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

Robert Justice

http://www.w3.org/2001/XMLSchema#string

S Leigh Verbois

http://www.w3.org/2001/XMLSchema#string

Vicki Goodman

http://www.w3.org/2001/XMLSchema#string

P304

107-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.12-1-107

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6574551

http://www.w3.org/2001/XMLSchema#string

P698

17227905

http://www.w3.org/2001/XMLSchema#string